Table 3.
Drug resistance-related risk factors univariate analysis
| 分组 | Total cases |
Resistant group |
Sensitive group |
P | ||
|---|---|---|---|---|---|---|
| Cases | Rate(%) | Cases | Rate(%) | |||
| FIGO Stages | ||||||
| I |
19 |
1 |
2.94 |
18 |
31.03 |
0.01 |
| II |
13 |
3 |
8.82 |
10 |
17.24 |
|
| III |
60 |
30 |
88.24 |
30 |
51.72 |
|
| IV |
0 |
0 |
0 |
0 |
0 |
|
| Differentiation | ||||||
| High |
15 |
5 |
14.71 |
10 |
17.24 |
0.298 |
| Moderate |
35 |
12 |
35.29 |
23 |
39.66 |
|
| Poorly |
42 |
17 |
50.00 |
25 |
43.10 |
|
| Histologic subtype | ||||||
| Serous cystadenocarcinoma |
58 |
24 |
70.59 |
34 |
58.62 |
0.872 |
| Mucinous cystadenocarcinoma |
8 |
4 |
11.76 |
4 |
6.90 |
|
| Endometrioid carcinoma |
4 |
1 |
2.94 |
3 |
5.17 |
|
| Clear cell carcinoma |
7 |
1 |
2.94 |
6 |
10.34 |
|
| Poorly differentiated adenocarcinoma | 15 | 4 | 11.76 | 11 | 18.87 | |